11 completed, 6 unknown, 4 recruiting, 2 active not recruiting. 12 Phase 2, 9 Not applicable, 1 Early Phase 1, 1 Phase 3, 1 Phase 4.
Follow palmidrol: new trials by email Literature Review of palmidrol trials Research Report on palmidrol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palmitoylethanolamide in Ulcerative Colitis Palmitoylethanolamide (PEA), Placebo - Ulcerative Colitis (UC) | Not applicable | Recruiting | Ain Shams University | 60 | 2026-08-15 | 2026-09-15 |
| Sleep and Stress Study Lavender Oil, Palmitoylethanolamide (PEA), Oleoylethanolamide - Sleep Disorder (Disorder), Stress | Phase 2 | Recruiting | RDC Clinical Pty Ltd | 240 | 2026-04-07 | 2026-04-23 |
| Palmitoylethanolamide Modulates Central Sensitisation and Neuroinflammation in Chronic Low Back Pain Palmitoylethanolamide - Chronic Low-back Pain | Not applicable | Recruiting | Beni-Suef University | 106 | 2026-01-01 | 2026-08-19 |
| Palmitoylethanolamide vs Ibuprofen for Pain After ESWL Palmitoylethanolamide (PEA), Ibuprofen (Brufen®) - Pain After Extracorporeal Shock Wave Lithotripsy, Palmitoylethanolamide | Not applicable | Completed | Benha University | 120 | 2026-01-01 | 2026-10-21 |
| Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy Levagen+, Placebo - Diabetic Peripheral Neuropathy | Phase 2 | Recruiting | RDC Clinical Pty Ltd | 80 | 2025-07-01 | 2025-07-23 |
| Study to Investigate the Potential Pharmacological Effect of Oral Palmitoylethanolamide (PEA) Therapy in the Management of Low Back Pain (Neuropathic Pain) 300 mg Palmitoylethanolamide (PEA) Phytosome®, 450 mg Palmitoylethanolamide (PEA) Phytosome®, Control group - Low Back Pain | Not applicable | Completed | Liaquat University of Medical & Health Sciences | 120 | 2025-01-28 | 2025-11-18 |
| Long-Term PEA Safety Study Palmitoylethanolamide (PEA), Placebo - Healthy, Safety | Phase 2 | Active not recruiting | RDC Clinical Pty Ltd | 200 | 2025-01-22 | 2026-09-09 |
| Palmitoylethanolamide for Chronic Inflammatory Pain Conditions Palmitoylethanolamide 600mg twice a day, placebo - Chronic Pain | Phase 2 | Unknown | Navy Medical Center San Diego | 80 | 2024-08-05 | 2024-08-15 |
| A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression Palmitoylethanolamide (PEA), Placebo, Treatment as Usual (TAU) - Bipolar Depression | Phase 2 | Completed | Rodrigo Machado-Vieira, MD, PhD, MSc | 34 | 2023-05-17 | 2026-08-13 |
| Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments Palmitoyl ethanolamide, Ketogenic diet - Migraine Disorders, Chronic Migraine | Unknown | IRCCS National Neurological Institute "C. Mondino" Foundation | 45 | 2023-05-10 | 2024-08-20 | |
| Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Below Knee Fracture Fixation Palmitoylethanolamide, Placebo - Tibial Fractures, Fibula Fracture | Phase 2 | Withdrawn | University of California, Irvine | 2023-05-01 | 2023-05-09 | |
| Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis palmitoylethanolamide, Placebo - Osteoarthritis, Knee | Not applicable | Completed | University of Maryland, Baltimore | 13 | 2023-03-22 | 2024-11-05 |
| PEA vs. Placebo for Major Depression Palmitoylethanolamide - Bipolar Depression, Major Depressive Disorder | Phase 2 | Unknown | The Israeli Medical Center for Alzheimer's | 100 | 2022-12-21 | 2023-10-02 |
| Efficacy of Phycocyanin and Palmitoylethanolamide for the Treatment of Chronic Prostatitis Symptoms FICOXPEA® is an oral combination of Phycocyanin, Palmitoylethanolamide and selenium - Chronic Prostatitis (CP), Chronic Prostatitis With Chronic Pelvic Pain Syndrome | Phase 4 | Completed | Clinica Urologica Molinette - Città della Saliute e della Scienza | 48 | 2022-11-02 | 2025-07-24 |
| Endocannabinoids, Stress, Craving And Pain Effects Study Palmitoylethanolamide, Placebo - Opioid Use Disorder | Early Phase 1 | Completed | Brigham and Women's Hospital | 12 | 2022-11-01 | 2025-10-20 |
| PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy Palmidrol, Placebo Administration, Quality-of-Life Assessment - Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 88 | 2022-05-16 | 2025-09-22 |
| PEA in Functional Dyspepsia Palmitoylethanolamide - Dyspepsia and Other Specified Disorders of Function of Stomach | Not applicable | Unknown | Universitaire Ziekenhuizen KU Leuven | 100 | 2021-11-29 | 2024-07-01 |
| The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema 1.5% Palmitoylethanolamide (PEA) sold as Levagen+, Placebo Comparator - Eczema, Atopic | Phase 2 / Phase 3 | Completed | RDC Clinical Pty Ltd | 72 | 2021-11-29 | 2023-11-18 |
| Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants N-Acetyl-L-cysteine (NAC), Echinacea purpurea, Curcumin - Immunity Disorders | Not applicable | Completed | Immunoflex Therapeutics Inc. | 32 | 2021-01-10 | 2022-02-16 |
| Effect of Palmitoylethanolamide on Proinflammatory Markers in Adults Recently Diagnosed With COVID-19 palmitoylethanolamide, Placebo, Curcumin - Inflammation, COVID19 | Not applicable | Completed | Arizona State University | 115 | 2020-10-20 | 2023-03-08 |
Showing 20 of 24. Sign in to see all of them.
Bipolar Disorder (2) · Chronic Pain (2) · Inflammation (2) · Pain (2) · Pain, Postoperative (2) · Tourette Syndrome (2) · Anxiety Disorders (1) · COVID-19 (1) · Colitis, Ulcerative (1) · Depressive Disorder, Major (1) · Dermatitis, Atopic (1) · Dyspepsia (1) · Fibula Fractures (1) · Glaucoma (1) · Hematologic Neoplasms (1)
RDC Clinical Pty Ltd (4) · Academic and Community Cancer Research United (1) · Ain Shams University (1) · Arizona State University (1) · Benha University (1) · Beni-Suef University (1) · Brigham and Women's Hospital (1) · Clinica Urologica Molinette - Città della Saliute e della Scienza (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · IRCCS National Neurological Institute "C. Mondino" Foundation (1) · Immunoflex Therapeutics Inc. (1) · Liaquat University of Medical & Health Sciences (1) · Navy Medical Center San Diego (1) · Neurothera Labs Inc. (1) · Rodrigo Machado-Vieira, MD, PhD, MSc (1)
United States (8) · Australia (4) · Egypt (3) · Italy (3) · Belgium (1) · Canada (1) · Germany (1) · Moldova (1) · Pakistan (1)
Alberto Pasetto, PhD (1) · Ariana Nelson, MD (1) · David Briskey, PhD (1) · Gurinder Raj, MD (1) · Hagar Ahmed Elessawy, Associate professor (1) · Hatem Elmoutaz Mahmoud, M.D (1) · Jennifer Klinedinst, PhD, MPH, RN (1) · Laura Rinaldi, MD (1) · Marc Hochberg, MD, MPH (1) · Mellar P Davis (1) · Michael H. Bloch, MD, MS (1) · Nagwa Ali Sabri, Professor (1) · RV Venkatesh (1) · Ramasamy Venkatesh (1)
PMID 10411041, PMID 19524353, PMID 23334883, PMID 31937091, PMID 36084236, PMID 38408443
P30CA015083 (1)